Annotation Detail
Information
- Associated Genes
- MET
- Associated Variants
-
MET AMPLIFICATION
(
ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 ) - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- 155 patients with lung adenocarcinomas underwent rebiopsy and genotyping (EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS, PIK3CA and FISH for MET and HER2) after the development of acquired resistance to EGFR inhibitors (gefitinib or erlotinib). MET amplification was seen in 4 of 75 patients tested (no baseline samples available). One patient had small cell transformation and MET amplification, two patients had EGFR T790M mutation and MET amplification.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1392
- Gene URL
- https://civic.genome.wustl.edu/links/genes/52
- Variant URL
- https://civic.genome.wustl.edu/links/variants/270
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Gefitinib,Erlotinib
- Evidence Level
- C
- Clinical Significance
- Resistance
- Pubmed
- 23470965